Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer

Zane T. Hammoud, Kenneth Kesler, M. K. Ferguson, R. J. Battafarrano, A. Bhogaraju, Nasser Hanna, R. Govindan, A. A. Mauer, M. Yu, Lawrence Einhorn

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

A variety of strategies, using chemotherapy, radiation therapy, and surgical resection have been employed in the treatment of locally advanced esophageal cancer. No strategy has proven superior, and poor long-term survival is anticipated. A survival benefit has been suggested for patients who achieve a pathologic complete response (pCR) following neoadjuvant chemoradiation therapy. We examined the collective results at three institutions of patients who achieved a pCR following neoadjuvant chemoradiation therapy. A retrospective, chart-based review was conducted. Kaplan-Meier calculations were used to determine overall and disease-free survival. Between 1995 and 2002, 229 patients were treated with neoadjuvant chemoradiation followed by surgery as a planned approach for locally advanced esophageal cancer. Forty-one patients (18%) demonstrated pCR and were the focus of this study. Histology was adenocarcinoma in 29, squamous in 10, and adenosquamous/undifferentiated in two patients. Forty patients were staged by endoscopic ultrasound prior to neoadjuvant therapy and all demonstrated a T-stage of 2 or higher, while 19 had evidence of nodal metastasis. Four patients died in the perioperative period. The remaining patients have been followed for an average of 46 months. Overall survival at 5 years was 56.4% and a median survival has not been reached. Esophageal cancer patients who demonstrate a pCR following neoadjuvant chemoradiation are a select subset who demonstrate excellent long-term survival. Identification of clinical variables or biomarkers predictive of pCR may therefore optimize treatment strategies of patients with locally advanced esophageal cancer.

Original languageEnglish
Pages (from-to)69-72
Number of pages4
JournalDiseases of the Esophagus
Volume19
Issue number2
DOIs
StatePublished - Apr 2006

Fingerprint

Neoadjuvant Therapy
Esophageal Neoplasms
Survival
Perioperative Period
Disease-Free Survival
Histology
Adenocarcinoma
Radiotherapy
Biomarkers
Neoplasm Metastasis
Drug Therapy

Keywords

  • Esophageal cancer
  • Esophagectomy
  • Neoadjuvant therapy
  • Pathologic complete response
  • Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer. / Hammoud, Zane T.; Kesler, Kenneth; Ferguson, M. K.; Battafarrano, R. J.; Bhogaraju, A.; Hanna, Nasser; Govindan, R.; Mauer, A. A.; Yu, M.; Einhorn, Lawrence.

In: Diseases of the Esophagus, Vol. 19, No. 2, 04.2006, p. 69-72.

Research output: Contribution to journalArticle

@article{79b242a66de24f75b42a5c02ee975402,
title = "Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer",
abstract = "A variety of strategies, using chemotherapy, radiation therapy, and surgical resection have been employed in the treatment of locally advanced esophageal cancer. No strategy has proven superior, and poor long-term survival is anticipated. A survival benefit has been suggested for patients who achieve a pathologic complete response (pCR) following neoadjuvant chemoradiation therapy. We examined the collective results at three institutions of patients who achieved a pCR following neoadjuvant chemoradiation therapy. A retrospective, chart-based review was conducted. Kaplan-Meier calculations were used to determine overall and disease-free survival. Between 1995 and 2002, 229 patients were treated with neoadjuvant chemoradiation followed by surgery as a planned approach for locally advanced esophageal cancer. Forty-one patients (18{\%}) demonstrated pCR and were the focus of this study. Histology was adenocarcinoma in 29, squamous in 10, and adenosquamous/undifferentiated in two patients. Forty patients were staged by endoscopic ultrasound prior to neoadjuvant therapy and all demonstrated a T-stage of 2 or higher, while 19 had evidence of nodal metastasis. Four patients died in the perioperative period. The remaining patients have been followed for an average of 46 months. Overall survival at 5 years was 56.4{\%} and a median survival has not been reached. Esophageal cancer patients who demonstrate a pCR following neoadjuvant chemoradiation are a select subset who demonstrate excellent long-term survival. Identification of clinical variables or biomarkers predictive of pCR may therefore optimize treatment strategies of patients with locally advanced esophageal cancer.",
keywords = "Esophageal cancer, Esophagectomy, Neoadjuvant therapy, Pathologic complete response, Survival",
author = "Hammoud, {Zane T.} and Kenneth Kesler and Ferguson, {M. K.} and Battafarrano, {R. J.} and A. Bhogaraju and Nasser Hanna and R. Govindan and Mauer, {A. A.} and M. Yu and Lawrence Einhorn",
year = "2006",
month = "4",
doi = "10.1111/j.1442-2050.2006.00542.x",
language = "English",
volume = "19",
pages = "69--72",
journal = "Diseases of the Esophagus",
issn = "1120-8694",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Survival outcomes of resected patients who demonstrate a pathologic complete response after neoadjuvant chemoradiation therapy for locally advanced esophageal cancer

AU - Hammoud, Zane T.

AU - Kesler, Kenneth

AU - Ferguson, M. K.

AU - Battafarrano, R. J.

AU - Bhogaraju, A.

AU - Hanna, Nasser

AU - Govindan, R.

AU - Mauer, A. A.

AU - Yu, M.

AU - Einhorn, Lawrence

PY - 2006/4

Y1 - 2006/4

N2 - A variety of strategies, using chemotherapy, radiation therapy, and surgical resection have been employed in the treatment of locally advanced esophageal cancer. No strategy has proven superior, and poor long-term survival is anticipated. A survival benefit has been suggested for patients who achieve a pathologic complete response (pCR) following neoadjuvant chemoradiation therapy. We examined the collective results at three institutions of patients who achieved a pCR following neoadjuvant chemoradiation therapy. A retrospective, chart-based review was conducted. Kaplan-Meier calculations were used to determine overall and disease-free survival. Between 1995 and 2002, 229 patients were treated with neoadjuvant chemoradiation followed by surgery as a planned approach for locally advanced esophageal cancer. Forty-one patients (18%) demonstrated pCR and were the focus of this study. Histology was adenocarcinoma in 29, squamous in 10, and adenosquamous/undifferentiated in two patients. Forty patients were staged by endoscopic ultrasound prior to neoadjuvant therapy and all demonstrated a T-stage of 2 or higher, while 19 had evidence of nodal metastasis. Four patients died in the perioperative period. The remaining patients have been followed for an average of 46 months. Overall survival at 5 years was 56.4% and a median survival has not been reached. Esophageal cancer patients who demonstrate a pCR following neoadjuvant chemoradiation are a select subset who demonstrate excellent long-term survival. Identification of clinical variables or biomarkers predictive of pCR may therefore optimize treatment strategies of patients with locally advanced esophageal cancer.

AB - A variety of strategies, using chemotherapy, radiation therapy, and surgical resection have been employed in the treatment of locally advanced esophageal cancer. No strategy has proven superior, and poor long-term survival is anticipated. A survival benefit has been suggested for patients who achieve a pathologic complete response (pCR) following neoadjuvant chemoradiation therapy. We examined the collective results at three institutions of patients who achieved a pCR following neoadjuvant chemoradiation therapy. A retrospective, chart-based review was conducted. Kaplan-Meier calculations were used to determine overall and disease-free survival. Between 1995 and 2002, 229 patients were treated with neoadjuvant chemoradiation followed by surgery as a planned approach for locally advanced esophageal cancer. Forty-one patients (18%) demonstrated pCR and were the focus of this study. Histology was adenocarcinoma in 29, squamous in 10, and adenosquamous/undifferentiated in two patients. Forty patients were staged by endoscopic ultrasound prior to neoadjuvant therapy and all demonstrated a T-stage of 2 or higher, while 19 had evidence of nodal metastasis. Four patients died in the perioperative period. The remaining patients have been followed for an average of 46 months. Overall survival at 5 years was 56.4% and a median survival has not been reached. Esophageal cancer patients who demonstrate a pCR following neoadjuvant chemoradiation are a select subset who demonstrate excellent long-term survival. Identification of clinical variables or biomarkers predictive of pCR may therefore optimize treatment strategies of patients with locally advanced esophageal cancer.

KW - Esophageal cancer

KW - Esophagectomy

KW - Neoadjuvant therapy

KW - Pathologic complete response

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=33645165199&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645165199&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2050.2006.00542.x

DO - 10.1111/j.1442-2050.2006.00542.x

M3 - Article

VL - 19

SP - 69

EP - 72

JO - Diseases of the Esophagus

JF - Diseases of the Esophagus

SN - 1120-8694

IS - 2

ER -